GlassScriptPhysician profile
Daniel Raymond Lomasney
NPI 1760813554
$1,876.67
in general payments reported to CMS, 2019-2025
22 companies · $374 in 2025
The $374 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $172 · 2022: $525 · 2023: $402 · 2024: $403 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,178.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $495.70 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $297.35 | 2021-2024 | Jornay Pm |
| Tris Pharma INC | $194.27 | 2021-2025 | Dyanavel Xr, Onyda Xr |
| Corium, LLC | $173.42 | 2022-2025 | Azstarys |
| Glaxosmithkline, LLC. | $145.01 | 2022-2025 | Bexsero, Rotarix, Pediarix |
| Collegium Pharmaceutical, INC. | $85.67 | 2025 | Jornay Pm |
| Cranial Technologies, INC | $73.98 | 2022-2024 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $61.40 | 2021-2022 | |
| Sanofi Pasteur INC. | $49.59 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $38.63 | 2021-2024 | Gardasil, Vaxelis, Vaxneuvance |
| Pfizer INC. | $36.63 | 2024 | |
| Seqirus USA INC | $33.31 | 2022-2025 | Flucelvax |
| Genentech USA, INC. | $29.89 | 2021 | |
| Adlon Therapeutics L.P. | $19.54 | 2021 | |
| Phadia US INC. | $19.02 | 2023 | Immunocap |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $18.52 | 2024 | Ycanth |
| Astrazeneca Pharmaceuticals LP | $18.30 | 2024 | Flumist Quadrivalent |
| Avion Pharmaceuticals | $17.91 | 2023 | Methylphenidate Hydrochloride |
| Boston Scientific Corporation | $17.80 | 2023 | |
| Kaleo, INC. | $17.40 | 2022 | |
| Alk-Abello, INC | $16.84 | 2024 | Grastek, Ragwitek, Odactra |
| Neos Therapeutics, LP | $16.49 | 2024 | Cotempla Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lomasney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.